Key result
Dual antiplatelet therapy (DAPT) is recommended for 12 months following percutaneous coronary intervention to mitigate the risk of late stent thrombosis with early-generation drug-eluting stents.
This review discusses the historical context and rationale for prolonging dual antiplatelet therapy to 12 months following PCI with early-generation drug-eluting stents.
Answers are grounded in this paper and cite their sources.
May support tailored DAPT durations post-PCI in CAD; leaves open optimal regimens pending higher-level evidence.
The dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor exerts protection against ischemic myocardial recurrences. During last two decades, DAPT has become the mainstay for treating patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), following the initial demonstration that DAPT was superior to anticoagulant therapy in these patients. Initially, and for many years, DAPT was prescribed for 2 to 6 months after PCI in important trials of stent implantation leading to the approval of early-generation drug-eluting stents (DES) by the US Food and Drug Administration. However, the subsequent increasing safety concerns related to the potential occurrence of late and very late stent thrombosis (ST) after implantation of early-generation DES lead to the recommendation of prolonging DAPT to 12 months by the American guidelines (1).
No takes yet. Share an insight, caveat, or question.
Gargiulo et al. (2017) conducted a review in coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Dual antiplatelet therapy (DAPT) was evaluated. Dual antiplatelet therapy (DAPT) is recommended for 12 months following percutaneous coronary intervention to mitigate the risk of late stent thrombosis with early-generation drug-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: